Invokamet is a once-daily drug that contains a combination of canagliflozin and metformin hydrochloride. Type 2 diabetes treatment guidelines from the American Association of Clinical Endocrinologists, the American College of Endocrinology and the American Diabetes Association recommend a dual treatment method for patients with high A1C levels. A1C is a measure of average blood glucose over the past three months, according to the report.
“Invokamet XR offers the convenience of once-daily dosing and provides physicians needed flexibility for tailoring treatment to the needs of type 2 diabetes patients, especially those with higher A1C levels,” said John Anderson, MD, of the Frist Clinic in Nashville, Tenn. “[P]hysicians can prescribe the XR formulation to adults when they are first diagnosed with type 2 diabetes or as additional therapy for people whose A1C levels are not well controlled with either agent alone.”
More articles on supply chain:
Ohio police race through anti-overdose drug supply
Active ingredient shortage puts Bristol-Myers Squibb cancer drug on backorder
Mylan CEO acknowledges company could have anticipated consumer concern over price hike
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
